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EssentialsThe added value of bleeding scores for identifying women with a high risk of excessive blood loss at childbirth is unknown.Prospective two‐center cohort study in pregnant women with follow‐up until childbirth.A history of excessive blood loss at childbirth is associated with a 30% increased risk of subsequent postpartum hemorrhage.Bleeding scores do not add to the identification of women who will develop postpartum hemorrhage.

1. INTRODUCTION {#rth212194-sec-0008}
===============

Postpartum hemorrhage continues to be a leading cause of maternal health problems worldwide.[1](#rth212194-bib-0001){ref-type="ref"}, [2](#rth212194-bib-0002){ref-type="ref"}, [3](#rth212194-bib-0003){ref-type="ref"}, [4](#rth212194-bib-0004){ref-type="ref"} Although risk factors are often known to be present during pregnancy and birth, postpartum hemorrhage frequently occurs unexpectedly.[5](#rth212194-bib-0005){ref-type="ref"}, [6](#rth212194-bib-0006){ref-type="ref"}, [7](#rth212194-bib-0007){ref-type="ref"} Also, women with known risk factors for postpartum hemorrhage frequently do not bleed excessively following childbirth. It has therefore proven difficult to develop a reliable prediction model for postpartum hemorrhage based on clinical peripartum risk factors.[5](#rth212194-bib-0005){ref-type="ref"}, [8](#rth212194-bib-0008){ref-type="ref"}, [9](#rth212194-bib-0009){ref-type="ref"}

In general clinical practice, assessment of bleeding risk is performed by assessing clinical history, performing a physical examination, and sometimes the use of screening coagulation tests.[10](#rth212194-bib-0010){ref-type="ref"}, [11](#rth212194-bib-0011){ref-type="ref"} However, coagulation testing to predict bleeding risk prior to invasive procedures was found to be not useful due to limited sensitivity and specificity of the tests and low prevalence of bleeding disorders.[12](#rth212194-bib-0012){ref-type="ref"}, [13](#rth212194-bib-0013){ref-type="ref"} The best results for prior assessment of bleeding risk come from more structured approaches to history taking by means of bleeding assessment tools (BATs), originally developed to determine the likelihood of the presence of a bleeding disorder (von Willebrand disease).[14](#rth212194-bib-0014){ref-type="ref"}, [15](#rth212194-bib-0015){ref-type="ref"}, [16](#rth212194-bib-0016){ref-type="ref"} In adults with von Willebrand disease, bleeding assessment tools have shown to be able to predict future bleeding events.[17](#rth212194-bib-0017){ref-type="ref"} Another very useful application of bleeding assessment tools would be the ability contribute to the identification of subjects who are more likely to bleed excessively *prior* to their exposure to invasive procedures, surgery and also childbirth.[18](#rth212194-bib-0018){ref-type="ref"} The main causes for postpartum hemorrhage are known to be obstetrical, but undiagnosed bleeding disorders can increase the risk of postpartum hemorrhage about threefold.[7](#rth212194-bib-0007){ref-type="ref"}, [19](#rth212194-bib-0019){ref-type="ref"} Since postpartum hemorrhage remains an event that could have serious consequences including severe acute maternal morbidity and mortality, it would be of great significance to have a reliable screening tool that could contribute to the identification of women with an increased risk of excessive blood loss prior to childbirth.

The aim of this study was to examine the added predictive value of the TeMpOH‐2 self‐BAT derived from the condensed MCMDM‐1VWD (Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease) BAT in the prediction of postpartum hemorrhage.

2. MATERIALS AND METHODS {#rth212194-sec-0009}
========================

2.1. Design and study population {#rth212194-sec-0010}
--------------------------------

We studied women who had been included in the TeMpOH‐2 (Towards better Prognostic and Diagnostic strategies for Major Obstetric Hemorrhage) study, a prospective cohort of pregnant women in the Netherlands between February 2015 and April 2018. The women were recruited during their pregnancy at the outpatient clinics and maternity wards from two of the three participating hospitals, the Leiden University Medical Centre in Leiden and the Isala Clinics in Zwolle. Included women were monitored for the occurrence of postpartum hemorrhage and followed until discharge from hospital after childbirth. At inclusion women were asked to complete a questionnaire containing a bleeding assessment tool. Answers to the questions of the bleeding assessment tool pertained to a woman\'s pre‐pregnancy condition. Postpartum hemorrhage was defined as any blood loss ≥1000‐mL blood loss within 24 hours after childbirth. Blood loss ≥2000 mL was a secondary end point. To include as many women as possible, study information was provided by a trained nurse at a set third trimester consultation that was scheduled for all pregnant women visiting the outpatient clinic. Study information was also handed out to women during regular visits to the outpatient clinic. Moreover, women scheduled for caesarean section, were provided with study information on a second occasion during hospitalization prior to surgery, and women admitted to the maternity ward overnight were visited by a research nurse in the morning and asked to participate in the study. For the present analysis we selected women from the TeMpOH‐2 cohort for whom a completed bleeding assessment tool providing us with a valid bleeding score and data on volume of blood loss following childbirth were available. Women below 18 years of age or a gestational age below 24 weeks at the time of birth were excluded. Known coagulation disorders or anticoagulant use were not exclusion criteria. Approval for the study was obtained by the Ethical Committee of the Leiden University Medical Centre (P13.246) and of the committee of the Isala Clinics. The study was registered at ClinicalTrials.gov (NCT02149472). Written informed consent was obtained from all participants. Bleeding assessment tools were completed by all women during pregnancy (always prior to childbirth) because of the possibility of recall bias when completing the bleeding assessment tool after birth.

2.2. Bleeding assessment tool {#rth212194-sec-0011}
-----------------------------

We adjusted the condensed MCMDM‐1VWD bleeding assessment tool to a written questionnaire that could be used as a self‐assessment bleeding score. Medical terminology was converted into lay language and detail was added to items that needed extra explanation or examples that would otherwise be given by an expert (Data [S1](#rth212194-sup-0001){ref-type="supplementary-material"}). The agreement between patient self‐assessment and expert assessment of the bleeding symptoms was evaluated and found to be excellent: eight women participating in the study completed the TeMpOH‐2 study self‐BAT (without assistance) followed by the condensed MCMDM‐1VWD (administered by an expert). In both questionnaires, the same scoring key is applied. Scores were equal in seven of the eight participants, and a difference of +1 was found in one woman.

2.3. Calculation of bleeding score {#rth212194-sec-0012}
----------------------------------

The questionnaire (derived from the condensed MCDM‐1VWD BAT) comprised 12 areas of bleeding: epistaxis, cutaneous, bleeding from minor wounds, oral cavity, gastrointestinal bleeding, tooth extraction, surgery, menorrhagia, postpartum hemorrhage, muscle hematoma, hemarthrosis, central nervous system bleeding. The condensed MCDM‐1VWD BAT as assessed in a primary care setting yielded a mean bleeding score in 100 healthy individuals of 0.16 with a range of normal bleeding scores from −3.2 to +3.6.[15](#rth212194-bib-0015){ref-type="ref"} Accordingly, we considered a score of ≥4 as abnormal.

2.4. Data collection {#rth212194-sec-0013}
--------------------

Participants completed the bleeding assessment tool either via a paper‐based or web‐based questionnaire. Results of the paper‐based questionnaire were scanned and evaluated by TeleForm. TeleForm is a software application that enables the creation of forms for data collection and reads the returned data by use of a scanner. After processing and verifying of the data by a trained operator, data were exported from TeleForm into a SPSS database for further analyses. The web‐based questionnaire was created in NetQ, an online questionnaire tool. Data were automatically exported to SPSS and then verified. Bleeding scores were calculated for all participants from the data derived from the bleeding assessment tool. Additional information was collected by well‐trained research nurses who performed comprehensive chart reviews. Data were recorded from medical files available at the maternity ward for the following parameters: maternal age at the time of birth, parity, gestational age, mode of birth, presence of preeclampsia or Hemolysis Elevated Liver Enzymes Low Platelet (HELLP) syndrome, presence of a coagulation disorder, anticoagulant use, and total volume of blood loss. Blood loss was measured by weighing gauzes and all other soaked materials and by the use of a collector bag and suction system in the operating theatre. In case women had experienced postpartum hemorrhage additional information was collected on cause of bleeding and treatment.

2.5. Statistical analyses {#rth212194-sec-0014}
-------------------------

Bleeding scores were calculated using the tool specific scoring key. Sensitivity, specificity, positive and negative predictive value and the area under the receiver operator curve (AUC\'s) were calculated to quantify test characteristics of the bleeding score in relation to the occurrence of postpartum hemorrhage defined as more than 1000‐mL blood loss (primary endpoint) as well as more than 2000‐mL blood loss. Positive and negative predictive value were also calculated for all separate items of the bleeding score (epistaxis, cutaneous, bleeding from minor wounds, oral cavity, gastrointestinal bleeding, tooth extraction, surgery, menorrhagia, postpartum hemorrhage, muscle hematoma, hemarthrosis, central nervous system bleeding). To evaluate the possibility of selection bias due to a high number of women with caesarean sections, sensitivity analyses were performed excluding women who gave birth by elective caesarean section.

3. RESULTS {#rth212194-sec-0015}
==========

3.1. Patient characteristics {#rth212194-sec-0016}
----------------------------

Over the 3‐year TeMpOH‐2 inclusion period, 1147 women for whom data were available on total volume of blood loss following childbirth, completed the bleeding assessment tool (Figure [1](#rth212194-fig-0001){ref-type="fig"}). Baseline characteristics are reported in Table [1](#rth212194-tbl-0001){ref-type="table"}. Women were on average 32 years of age (IQR 29‐35), gave birth at a median gestational age of 39.0 weeks (IQR 38.1‐40.3) and 30% delivered by caesarean section. In our cohort (197/1147) 17.2% of women experienced postpartum hemorrhage ≥1000 mL and (55/1147) 4.8% of women lost more than 2000 mL of blood following birth. Primary cause of postpartum hemorrhage was uterine atony or retained placenta in 68% of women and 25% of bleeds were the result of a surgical cause. Bleeding scores ranged from −3 to 13, with a median of 1 (IQR −1 to 3). Of the women in our cohort, (147/1147) 12.8% had an abnormal bleeding score of ≥4. The distribution of bleeding scores plotted to categories of increasing volume of blood loss is shown in Figure [2](#rth212194-fig-0002){ref-type="fig"}. The bubble plot displays number of women per bleeding score categorized in increasing volumes of blood loss. Larger bubbles represent a higher patient count.

![Inclusion flowchart](RTH2-3-277-g001){#rth212194-fig-0001}

###### 

Characteristics of participants[a](#rth212194-note-0002){ref-type="fn"}

                                         Total                 LUMC                  Isala                 Postpartum hemorrhage ≥1000 mL   
  -------------------------------------- --------------------- --------------------- --------------------- -------------------------------- ---------------------
  Patients                               1147                  818                   329                   950                              197
  Age in years                           32 (29 to 35)         32 (30 to 35)         31 (28 to 35)         32 (29 to 35)                    32 (29 to 36)
  Nulliparity                            39%                   41%                   33%                   38%                              43%
  Gestational age in weeks               39.0 (38.1 to 40.3)   38.9 (37.9 to 40.1)   39.1 (38.1 to 40.6)   39.0 (38.1 to 40.3)              39.1 (38.0 to 40.6)
  Bleeding score                         1 (−1 to 2)           1 (−1 to 2)           1 (0 to 2)            1 (−1 to 2)                      1 (0 to 3)
  Mode of birth                                                                                                                             
  Caesarean section                      30%                   33%                   23%                   30%                              27%
  Vaginal                                70%                   67%                   77%                   70%                              73%
  Comorbidity                                                                                                                               
  Preeclampsia/HELLP                     5%                    5%                    4%                    4%                               9%
  Anticoagulant use                      8%                    10%                   3%                    8%                               7%
  Known coagulation disorder (VWD)       1%                    5%                    2%                    1%                               0%
  Total volume of blood loss in liters   0.4 (0.3 to 0.7)      0.4 (0.2 to 0.7)      0.4 (0.3 to 0.6)      0.3 (0.2 to 0.5)                 1.5 (1.2 to 2.0)
  PPH ≥1000 mL                           17%                   17%                   16%                   NA                               NA
  PPH ≥2000 mL                           5%                    4%                    4%                    NA                               NA

PPH, postpartum hemorrhage; VWD, von Willebrand disease.

Values are median (25‐75 percentile) or percent.

John Wiley & Sons, Ltd

![Bubble plot of bleeding score versus volume of blood loss](RTH2-3-277-g002){#rth212194-fig-0002}

3.2. Discriminative ability of the bleeding score {#rth212194-sec-0017}
-------------------------------------------------

The ability of the score to discriminate women with postpartum hemorrhage ≥1000 mL from women without postpartum hemorrhage was poor, area under receiver operating curve 0.53 (95% CI 0.49‐0.58). For postpartum hemorrhage exceeding 2000 mL of blood loss the area under receiver operating curve was 0.60 (95% CI 0.52‐0.68), showing an increase but still a rather poor discriminative power. Among 147 women with an abnormal bleeding score (≥4) the incidence of postpartum hemorrhage of ≥1000 mL was 18.4% (n = 27), and the incidence of postpartum hemorrhage exceeding 2000 mL was 8.8% (n = 13). Of the 1000 women with a normal bleeding score, 170 (17%) developed postpartum hemorrhage ≥1000 mL and 42 (4.2%) developed blood loss exceeding 2000 mL (Table [2](#rth212194-tbl-0002){ref-type="table"}). Results of the sensitivity analyses excluding women with an elective caesarean section were similar to those of the main analyses (Table [S1](#rth212194-sup-0001){ref-type="supplementary-material"}).

###### 

Sensitivity and specificity, positive and negative predictive value of an abnormal bleeding score[a](#rth212194-note-0020){ref-type="fn"} for the occurrence of postpartum hemorrhage ≥1000 mL and ≥2000 mL

  Bleeding score and PPH   AUC (95% CI)       Sensitivity (95% CI)   Specificity (95% CI)   NPV (95% CI)       PPV (95% CI)
  ------------------------ ------------------ ---------------------- ---------------------- ------------------ ------------------
  ≥1000 mL                 0.53 (0.49‐0.58)   13.7 (9.39‐19.5)       87.4 (85.0‐89.4)       83.0 (80.5‐85.2)   18.4 (12.7‐25.8)
  ≥2000 mL                 0.60 (0.52‐0.68)   23.6 (13.7‐37.3)       87.7 (85.6‐89.6)       95.8 (94.3‐96.9)   8.8 (5.0‐14.9)

AUC, area under the curve; CI, confidence interval; PPH, postpartum hemorrhage.

abnormal bleeding score is defined as score ≥4.

John Wiley & Sons, Ltd

3.3. Bleeding symptoms {#rth212194-sec-0018}
----------------------

A history of postpartum hemorrhage was associated with postpartum hemorrhages of ≥1000 mL and ≥2000 mL. Epistaxis, postsurgery blood loss and a history of postpartum hemorrhage were associated with the development of blood loss exceeding 2000 mL (Table [3](#rth212194-tbl-0003){ref-type="table"}). A total of 122 women had a positive score on epistaxis or postsurgery blood loss; 13 (10.7%) of them developed blood loss exceeding 2000 mL.

###### 

Sensitivity and specificity, positive and negative predictive value of bleeding symptoms for the occurrence of postpartum hemorrhage ≥1000 mL and ≥2000 mL[a](#rth212194-note-0005){ref-type="fn"}

                           Sensitivity (%)   Specificity (%)   NPV (%)                                      PPV (%)
  ------------------------ ----------------- ----------------- -------------------------------------------- ---------
  Epistaxis                                                                                                 
  PPH 1000                 4.6               95.5              82.8                                         17.3
  PPH 2000                 10.9              95.8              95.5                                         11.5
  Cutaneous                                                                                                 
  PPH 1000                 15.2              87.5              83.3                                         20.1
  PPH 2000                 18.2              87.3              95.5                                         6.7
  Minor wounds                                                                                              
  PPH 1000                 3.6               95.8              82.7                                         14.9
  PPH 2000                 3.6               95.9              95.2                                         4.3
  Oral Cavity                                                                                               
  PPH 1000                 66.0              31.2              81.5                                         16.6
  PPH 2000                 63.6              31.4              95.5                                         4.5
  Gastrointestinal                                                                                          
  PPH 1000                 2.5               97.4              82.8                                         16.7
  PPH 2000                 1.8               97.3              95.2                                         3.3
  Tooth extraction                                                                                          
  PPH 1000                 2.5               95.7              82.6                                         10.9
  PPH 2000                 3.6               96.0              95.2                                         4.3
  Surgery                                                                                                   
  PPH 1000                 8.1               93.5              83.1                                         20.5
  PPH 2000                 12.7              93.5              95.5                                         9.0
  Menorrhagia                                                                                               
  PPH 1000                 16.2              82.8              82.7                                         16.4
  PPH 2000                 14.5              82.9              95.1                                         4.1
  PPH                                                                                                       
  PPH 1000                 30.5              84.2              85.4                                         28.6
  PPH 2000                 40.0              82.8              96.5                                         10.5
  Muscle hematoma                                                                                           
  PPH 1000                 4.1               96.4              82.9                                         19.0
  PPH 2000                 1.8               96.2              95.1                                         2.4
  Hemarthrosis                                                                                              
  PPH 1000                 1.5               99.3              82.9                                         30.0
  PPH 2000                 0.0               99.1              NA[b](#rth212194-note-0008){ref-type="fn"}   NA
  Central nervous system                                                                                    
  PPH 1000                 0.0               99.8              NA                                           NA
  PPH 2000                 0.0               99.8              NA                                           NA
  Epistaxis and surgery                                                                                     
  PPH 1000                 12.2              89.7              83.1                                         19.7
  PPH 2000                 10.7              90.0              95.9                                         10.7

PPH, postpartum hemorrhage.

Incidence of PPH 1000 mL in the cohort was 17.2%. Incidence of PPH 2000 L in the cohort was 4.2%.

Not calculated because of small numbers.

John Wiley & Sons, Ltd

4. DISCUSSION {#rth212194-sec-0019}
=============

This prospective two‐center cohort study describes the usefulness of a bleeding assessment tool to predict postpartum hemorrhage. In our cohort of 1147 women, the ability of the bleeding score to contribute to the discrimination between women with and without postpartum hemorrhage was poor.

Our results suggest that a questionnaire does not contribute to the identification of women who will develop postpartum hemorrhage. Since the main causes for postpartum hemorrhage are obstetrical it might be not surprising that a tool initially developed for the diagnosis of bleeding disorders does not associate with postpartum hemorrhage. However, adding two questions on history of nosebleeds and postsurgery blood loss to a standard medical history did contribute to the identification of women with a higher risk of larger bleeds. Thus, especially in women with already known risk factors for postpartum hemorrhage, knowledge of an abnormal bleeding score could be of added value while composing a personalized birth plan.

4.1. Strength and limitations of this study {#rth212194-sec-0020}
-------------------------------------------

A strength of our study is that we included a large cohort of 1147 pregnant women who had completed a bleeding assessment tool prior to childbirth with complete follow‐up until childbirth. To rule out the possibility of recall bias, the questionnaires were only completed by women before giving birth. Moreover, we used a self‐ BAT derived from the validated condensed MCMDM‐1VWD‐BAT which was proven to be a reliable tool.

We can\'t rule out the presence of bias in our study. A first possible source of bias is selection bias. In our cohort, the incidence of postpartum hemorrhage was higher than expected (17.2% vs expected 6%‐8%). This could be a result of the fact that the TeMpOH‐2 study included women in a university hospital (LUMC) and a non‐university hospital with a neonatal intensive care unit department on site, resulting in a population with a higher a priori risk of postpartum hemorrhage. Another possible explanation for the higher incidence of postpartum hemorrhage is the known underestimation of volume of blood loss in case of visual estimation. Volume of blood loss in theTeMpOH‐2 study was objectively measured, which could have led to a more realistic, yet higher, incidence of postpartum hemorrhage. Yet, if anything, a higher incidence might have influenced the predictive value of the questionnaire in a positive way.[22](#rth212194-bib-0022){ref-type="ref"},[23](#rth212194-bib-0023){ref-type="ref"} We therefore infer that the poor predictive value of our questionnaire is not the result of selection bias.

A second possible source of bias is misclassification of the endpoint postpartum hemorrhage. Volume of blood loss was supposed to be weighed in accordance with the study protocol, but we cannot rule out that sporadically weighing was complemented by visual estimation. When visual estimation is used, it is well‐known that volume of blood loss is in most cases underestimated.[24](#rth212194-bib-0024){ref-type="ref"} This may have led to potential misclassification of women in our cohort, which in this case may have caused an underestimation of incidence of postpartum hemorrhage.

Notwithstanding the high incidence of postpartum hemorrhage, the discriminative power of our bleeding score to detect women with increased risk of postpartum hemorrhage was poor. This could mean, that the predictive ability of the bleeding score in a more general population of pregnant women is even worse.

4.2. Comparison with other studies {#rth212194-sec-0021}
----------------------------------

To the best of our knowledge, this study is the first to examine the value of bleeding scores evaluated during pregnancy as a screening tool for the identification of women with an increased risk of excessive blood loss postpartum. Our findings corroborate results of previous studies in different patient populations. In a cohort of 7730 pediatric patients undergoing adenotonsillectomy, the efficacy of a preoperative bleeding questionnaire and coagulation screening in predicting hemorrhage associated with the procedure was studied.[18](#rth212194-bib-0018){ref-type="ref"} When both an abnormal bleeding score and positive coagulation screening were combined, a statistically slightly higher likelihood of postoperative bleeding was found. However, an abnormal bleeding score without the additional coagulation screen did not have any predictive value for the occurrence of postsurgery hemorrhage. In a study in von Willebrand disease families (affected and unaffected family members), the association between spontaneous mucocutaneous bleeding symptoms and bleeding after tooth extraction or surgery was evaluated.[20](#rth212194-bib-0020){ref-type="ref"} The mucocutaneous bleeding score showed a predictive value similar to von Willebrand factor level for bleeding after tooth extraction (AUC 0.71) and an even better value for prediction of bleeding after surgery (AUC 0.78). In the area of von Willebrand disease, bleeding scores are used for their high negative predictive value, indicating that a normal bleeding score can help exclude a clinically significant bleeding disorder.[25](#rth212194-bib-0025){ref-type="ref"} In line with this, in a study of 217 individuals being prospectively investigated for von Willebrand disease, seventeen individuals with negative bleeding scores underwent major surgery, and none experienced significant bleeding. No previous studies were found that examined the predictive value of the use of bleeding scores in the field of childbirth. In contrast with von Willebrand disease, postpartum hemorrhage is a condition that is known for its multifactorial origin. We have assessed that a high bleeding score can to a certain extent contribute to an individual patients risk assessment prior to birth. However, the question whether postpartum hemorrhage will actually occur, can only be answered during the course of active bleeding, depending on the obstetric challenges in tone, tissue, trauma and thrombin that will develop along the way.[19](#rth212194-bib-0019){ref-type="ref"}

4.3. Clinical implications {#rth212194-sec-0022}
--------------------------

No evidence was found to support adding a bleeding assessment tool to the review of a pregnant woman\'s medical history for the prediction of postpartum hemorrhages of ≥1000 mL. However, adding two questions on history of nosebleeds and postsurgery blood loss to a standard medical history could enable a clinician to identify women with a higher risk of postpartum hemorrhage exceeding 2000 mL. Clinicians should contemplate whether they find this of clinical significance for individual patients.

5. CONCLUSION {#rth212194-sec-0023}
=============

When used as a screening tool contributing to the identification of pregnant women with an increased risk of postpartum hemorrhage prior to childbirth, a bleeding questionnaire lacks discriminative power. We found no evidence to support the added value of a bleeding assessment tool for the prediction of postpartum hemorrhage.
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